Francois Benard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1434791/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. Journal of the American College of Cardiology, 2007, 50, 2002-2012.	2.8	403
2	Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1345.	2.1	261
3	Metabolic Imaging of Malignant Pleural Mesothelioma With Fluorodeoxyglucose Positron Emission Tomography. Chest, 1998, 114, 713-722.	0.8	237
4	Whole-body FDG-PET imaging in the management of patients with cancer. Seminars in Nuclear Medicine, 2002, 32, 35-46.	4.6	178
5	Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Seminars in Nuclear Medicine, 2003, 33, 148-162.	4.6	159
6	Increasing Benefit From Revascularization Is Associated With Increasing Amounts of Myocardial Hibernation. JACC: Cardiovascular Imaging, 2009, 2, 1060-1068.	5.3	159
7	Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. Journal of Nuclear Medicine, 2004, 45, 214-9.	5.0	143
8	An Organotrifluoroborate for Broadly Applicable One‣tep ¹⁸ F‣abeling. Angewandte Chemie - International Edition, 2014, 53, 11876-11880.	13.8	139
9	A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1202-1222.	6.4	131
10	¹⁸ F-Fluorination of Unactivated C–H Bonds in Branched Aliphatic Amino Acids: Direct Synthesis of Oncological Positron Emission Tomography Imaging Agents. Journal of the American Chemical Society, 2017, 139, 3595-3598.	13.7	119
11	Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer. Clinical Nuclear Medicine, 2001, 26, 6-9.	1.3	109
12	Cyclotron production of 99mTc: Experimental measurement of the 100Mo(p,x)99Mo, 99mTc and 99gTc excitation functions from 8 to 18 MeV. Nuclear Medicine and Biology, 2011, 38, 907-916.	0.6	106
13	Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18f-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope, 1999, 109, 970-975.	2.0	105
14	PHTHALOCYANINE AND NAPHTHALOCYANINE PHOTOSENSITIZED OXIDATION OF 2â€2â€ÐEOXYGUANOSINE. Photochemistry and Photobiology, 1992, 55, 809-814.	2.5	101
15	Impact of Time-of-Flight PET on Whole-Body Oncologic Studies: A Human Observer Lesion Detection and Localization Study. Journal of Nuclear Medicine, 2011, 52, 712-719.	5.0	94
16	Can the standardized uptake value characterize primary brain tumors on FDG-PET?. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1501-1509.	6.4	87
17	Image-derived input function in dynamic human PET/CT: methodology and validation with 11C-acetate and 18F-fluorothioheptadecanoic acid in muscle and 18F-fluorodeoxyglucose in brain. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1539-1550.	6.4	86
18	A Prospective Study on ¹⁸ F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1587-1593.	5.0	84

#	Article	IF	CITATIONS
19	Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation. Nature Chemical Biology, 2022, 18, 963-971.	8.0	83
20	Implementation of Multi-Curie Production of ^{99m} Tc by Conventional Medical Cyclotrons. Journal of Nuclear Medicine, 2014, 55, 1017-1022.	5.0	82
21	Novel Matrix Metalloproteinase Inhibitor [18F]Marimastat-Aryltrifluoroborate as a Probe for <i>In vivo</i> Positron Emission Tomography Imaging in Cancer. Cancer Research, 2010, 70, 7562-7569.	0.9	79
22	Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Research, 2005, 7, 153-62.	5.0	77
23	Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. European Journal of Cancer, 2007, 43, 536-543.	2.8	77
24	Evaluation of ⁶⁴ Cu-Labeled Bifunctional Chelate–Bombesin Conjugates. Bioconjugate Chemistry, 2011, 22, 1729-1735.	3.6	77
25	Preclinical Evaluation of a High-Affinity ¹⁸ F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging. Journal of Nuclear Medicine, 2014, 55, 1499-1505.	5.0	77
26	One-step 18F labeling of biomolecules using organotrifluoroborates. Nature Protocols, 2015, 10, 1423-1432.	12.0	76
27	Enhancing Treatment Efficacy of ¹⁷⁷ Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. Molecular Pharmaceutics, 2018, 15, 5183-5191.	4.6	75
28	Prognostic value of FDG PET imaging in malignant pleural mesothelioma. Journal of Nuclear Medicine, 1999, 40, 1241-5.	5.0	75
29	Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Journal of Nuclear Medicine, 2003, 44, 1225-31.	5.0	74
30	Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjugate Chemistry, 2019, 30, 487-502.	3.6	73
31	Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models. EJNMMI Research, 2016, 6, 40.	2.5	71
32	Siteâ€5elective, Lateâ€5tage Câ^'H ¹⁸ Fâ€Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging. Angewandte Chemie - International Edition, 2018, 57, 12733-12736.	13.8	71
33	18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids, 2002, 67, 765-775.	1.8	68
34	Synthesis and evaluation of ¹⁸ F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 249-255.	5.2	63
35	Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging–Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	60
36	Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics, 2017, 7, 4322-4339.	10.0	59

#	Article	IF	CITATIONS
37	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2021, 137, 929-938.	1.4	57
38	Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. Journal of Nuclear Medicine, 1995, 36, 241-3.	5.0	56
39	An automated module for the separation and purification of cyclotron-produced 99mTcO4â^'. Nuclear Medicine and Biology, 2012, 39, 551-559.	0.6	53
40	44gSc production using a water target on a 13MeV cyclotron. Nuclear Medicine and Biology, 2014, 41, 401-406.	0.6	52
41	18F-AmBF3-MJ9: A novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorganic and Medicinal Chemistry, 2015, 23, 1500-1506.	3.0	51
42	The deposition of smooth metallic molybdenum from aqueous electrolytes containing molybdate ions. Electrochemistry Communications, 2012, 15, 78-80.	4.7	50
43	Quantitative gated PET for the assessment of left ventricular function in small animals. Journal of Nuclear Medicine, 2003, 44, 1655-61.	5.0	50
44	PET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with ⁶⁸ Ga-Labeled Benzenesulfonamides. Molecular Pharmaceutics, 2016, 13, 1137-1146.	4.6	49
45	Monosodium Glutamate Reduces ⁶⁸ Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model. Journal of Nuclear Medicine, 2018, 59, 1865-1868.	5.0	49
46	Singles transmission scans performed post-injection for quantitative whole body PET imaging. IEEE Transactions on Nuclear Science, 1997, 44, 1329-1335.	2.0	48
47	Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX–Targeted PET Imaging. Journal of Nuclear Medicine, 2015, 56, 1434-1440.	5.0	48
48	<i>In Vivo</i> Radioimaging of Bradykinin Receptor B1, a Widely Overexpressed Molecule in Human Cancer. Cancer Research, 2015, 75, 387-393.	0.9	48
49	Fluorescent Isoindole Crosslink (FIICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction. Angewandte Chemie - International Edition, 2019, 58, 14120-14124.	13.8	47
50	Machine Learning in Nuclear Medicine: Part 1—Introduction. Journal of Nuclear Medicine, 2019, 60, 451-458.	5.0	47
51	Theoretical modeling of yields for proton-induced reactions on natural and enriched molybdenum targets. Physics in Medicine and Biology, 2011, 56, 5469-5484.	3.0	46
52	Direct Production of 99mTc via 100Mo(p,2n) on Small Medical Cyclotrons. Physics Procedia, 2015, 66, 383-395.	1.2	46
53	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. Blood, 2020, 136, 2803-2811.	1.4	46
54	Insight into the Development of PET Radiopharmaceuticals for Oncology. Cancers, 2020, 12, 1312.	3.7	46

#	Article	IF	CITATIONS
55	Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nuclear Medicine and Biology, 2004, 31, 761-770.	0.6	45
56	Effects of Linker Modification on Tumor-to-Kidney Contrast of ⁶⁸ Ga-Labeled PSMA-Targeted Imaging Probes. Molecular Pharmaceutics, 2018, 15, 3502-3511.	4.6	45
57	The Effect of Insulin on the Intracellular Distribution of 14(R,S)-[18F]Fluoro-6-thia-heptadecanoic Acid in Rats. Molecular Imaging and Biology, 2006, 8, 237-244.	2.6	43
58	A Small Animal Positron Emission Tomography Study of the Effect of Chemotherapy and Hormonal Therapy on the Uptake of 2-Deoxy-2-[F-18]fluoro-d-glucose in Murine Models of Breast Cancer. Molecular Imaging and Biology, 2007, 9, 144-150.	2.6	43
59	Production of Y-86 and other radiometals for research purposes using a solution target system. Nuclear Medicine and Biology, 2015, 42, 842-849.	0.6	42
60	Design, synthesis and evaluation of ¹⁸ F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 722-730.	5.2	42
61	²²⁵ Ac-H ₄ py4pa for Targeted Alpha Therapy. Bioconjugate Chemistry, 2021, 32, 1348-1363.	3.6	42
62	Quantitative myocardial perfusion and coronary reserve in rats with 13N-ammonia and small animal PET: impact of anesthesia and pharmacologic stress agents. Journal of Nuclear Medicine, 2004, 45, 1924-30.	5.0	42
63	Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3212-3216.	2.2	41
64	Synthesis and Evaluation of a Macrocyclic Actiniumâ€⊋25 Chelator, Quality Control and In Vivo Evaluation of ²²⁵ Acâ€crownâ€Î±MSH Peptide. Chemistry - A European Journal, 2020, 26, 11435-11440.	3.3	41
65	Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients. Molecular Imaging and Biology, 2006, 8, 348-354.	2.6	40
66	Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine–bombesin conjugate. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2424-2427.	2.2	40
67	Functionally Versatile and Highly Stable Chelator for ¹¹¹ In and ¹⁷⁷ Lu: Proof-of-Principle Prostate-Specific Membrane Antigen Targeting. Bioconjugate Chemistry, 2019, 30, 1539-1553.	3.6	40
68	¹⁷⁷ Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio. Journal of Nuclear Medicine, 2021, 62, 521-527.	5.0	40
69	Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. Journal of Nuclear Medicine, 2006, 47, 559-65.	5.0	39
70	Total Solid-Phase Synthesis of NOTA-Functionalized Peptides for PET Imaging. Organic Letters, 2010, 12, 280-283.	4.6	38
71	¹⁸ F-Trifluoroborate Derivatives of [Des-Arg ¹⁰]Kallidin for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Molecular Pharmaceutics, 2015, 12, 974-982.	4.6	38
72	Medical Isotope Production at TRIUMF – from Imaging to Treatment. Physics Procedia, 2017, 90, 200-208.	1.2	38

5

#	Article	IF	CITATIONS
73	High-Grade Glioma Radiation Therapy Target Volumes and Patterns of Failure Obtained From Magnetic Resonance Imaging and 18F-FDOPA Positron Emission Tomography Delineations From Multiple Observers. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1100-1106.	0.8	37
74	<i>p</i> -NO ₂ –Bn–H ₄ neunpa and H ₄ neunpa–Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and ¹¹¹ In Immuno-Single Photon Emission Computed Tomography Imaging. Bioconjugate Chemistry, 2017, 28, 2145-2159.	3.6	37
75	Preclinical Melanoma Imaging with ⁶⁸ Ga-Labeled α-Melanocyte-Stimulating Hormone Derivatives Using PET. Theranostics, 2017, 7, 805-813.	10.0	37
76	Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11β-Methoxy-16α- ¹⁸ F-Fluoroestradiol Using Serial Whole-Body PET/CT. Journal of Nuclear Medicine, 2009, 50, 100-107.	5.0	36
77	[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 950-953.	2.2	36
78	¹⁸ F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models. Journal of Nuclear Medicine, 2017, 58, 367-373.	5.0	36
79	Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 21.	3.9	35
80	N-(N-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: A potential ligand for PET imaging of σ receptors. Nuclear Medicine and Biology, 1997, 24, 671-676.	0.6	34
81	Novel Radiolabeled Peptides for Breast and Prostate Tumor PET Imaging: ⁶⁴ Cu/and ⁶⁸ Ga/NOTA-PEG-[<scp>d</scp> -Tyr ⁶ ,î²Ala ¹¹ ,Thi ¹³ ,Nle <sup Bioconjugate Chemistry, 2012, 23, 1687-1693.</sup)> 1346 /sup:	>] B ₿N(6–
82	Melanoma Imaging Using ¹⁸ F-Labeled α-Melanocyte-Stimulating Hormone Derivatives with Positron Emission Tomography. Molecular Pharmaceutics, 2018, 15, 2116-2122.	4.6	31
83	Metformin Discontinuation prior to FDG PET/CT: A Randomized Controlled Study to Compare 24- and 48-hour Bowel Activity. Radiology, 2018, 289, 418-425.	7.3	31
84	Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening. European Journal of Cancer, 2007, 43, 1180-1187.	2.8	29
85	[11C]Acetate rest–stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats. Nuclear Medicine and Biology, 2012, 39, 287-294.	0.6	29
86	A new18F-heteroaryltrifluoroborate radio-prosthetic with greatly enhanced stability that is labelled by18F–19F-isotope exchange in good yield at high specific activity. MedChemComm, 2014, 5, 171-179.	3.4	29
87	Electrostatic Effects Accelerate Decatungstate-Catalyzed C–H Fluorination Using [¹⁸ F]- and [¹⁹ F]NFSI in Small Molecules and Peptide Mimics. ACS Catalysis, 2019, 9, 8276-8284.	11.2	29
88	Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 161±-position of fulvestrant (faslodex; ICI 182,780). Nuclear Medicine and Biology, 2004, 31, 691-698.	0.6	28
89	Regional Cerebral Glucose Metabolism in Healthy Volunteers Determined by Fluordeoxyglucose Positron Emission Tomography. Clinical Nuclear Medicine, 2000, 25, 596-602.	1.3	28
90	Comparative study of 64Cu/NOTA-[D-Tyr6,βAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Research, 2012, 2, 8.	2.5	27

#	Article	IF	CITATIONS
91	Theoretical dosimetry estimations for radioisotopes produced by proton-induced reactions on natural and enriched molybdenum targets. Physics in Medicine and Biology, 2012, 57, 1499-1515.	3.0	26
92	Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1365-1371.	2.1	25
93	Radiometals from liquid targets: 94mTc production using a standard water target on a 13MeV cyclotron. Applied Radiation and Isotopes, 2012, 70, 2308-2312.	1.5	25
94	A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors. Pharmaceuticals, 2020, 13, 199.	3.8	25
95	The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study. Journal of Nuclear Medicine, 2021, 62, 81-87.	5.0	25
96	A comparison of segmentation and emission subtraction for singles transmission in PET. IEEE Transactions on Nuclear Science, 1998, 45, 1212-1218.	2.0	24
97	Synthesis and evaluation of 18F-labeled tertiary benzenesulfonamides for imaging carbonic anhydrase IX expression in tumours with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3064-3068.	2.2	24
98	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	5.0	24
99	[11C] Acetoacetate Utilization by Breast and Prostate Tumors: a PET and Biodistribution Study in Mice. Molecular Imaging and Biology, 2008, 10, 217-223.	2.6	23
100	2-[18F]Fluoroethanol and 3-[18F]fluoropropanol: facile preparation, biodistribution in mice, and their application as nucleophiles in the synthesis of [18F]fluoroalkyl aryl ester and ether PET tracers. Nuclear Medicine and Biology, 2013, 40, 850-857.	0.6	23
101	Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89 Zr-labeled antibodies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 708-712.	2.2	23
102	Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE. Nuclear Medicine and Biology, 2018, 66, 10-17.	0.6	23
103	Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue. ACS Omega, 2019, 4, 1470-1478.	3.5	23
104	[^{nat/44} Sc(pypa)] ^{â^`} : Thermodynamic Stability, Radiolabeling, and Biodistribution of a Prostate-Specific-Membrane-Antigen-Targeting Conjugate. Inorganic Chemistry, 2020, 59, 1985-1995.	4.0	23
105	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). Blood, 2014, 124, 392-392.	1.4	23
106	Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Contemporary Clinical Trials, 2003, 24, 776-794.	1.9	22
107	Automated synthesis of 11C-acetoacetic acid, a key alternate brain fuel to glucose. Applied Radiation and Isotopes, 2007, 65, 934-940.	1.5	22
108	[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1473-1479.	6.4	22

#	Article	IF	CITATIONS
109	[11C]-Acetoacetate PET imaging: a potential early marker for cardiac heart failure. Nuclear Medicine and Biology, 2014, 41, 863-870.	0.6	22
110	Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 4.	3.9	22
111	A Metal-Free DOTA-Conjugated ¹⁸ F-Labeled Radiotracer: [¹⁸ F]DOTA-AMBF ₃ -LLP2A for Imaging VLA-4 Over-Expression in Murine Melanoma with Improved Tumor Uptake and Greatly Enhanced Renal Clearance. Bioconjugate Chemistry. 2019. 30. 1210-1219.	3.6	22
112	Clinical evaluation of processing techniques for attenuation correction with 137Cs in whole-body PET imaging. Journal of Nuclear Medicine, 1999, 40, 1257-63.	5.0	22
113	Cardiac studies in rats with /sup 11/C-acetate and PET: a comparison with /sup 13/N-ammonia. IEEE Transactions on Nuclear Science, 2002, 49, 2322-2327.	2.0	21
114	Siteâ€5elective, Lateâ€5tage Câ^'H ¹⁸ Fâ€Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging. Angewandte Chemie, 2018, 130, 12915-12918.	2.0	21
115	Mechanism of Reduced Myocardial Glucose Utilization During Acute Hypertriglyceridemia in Rats. Molecular Imaging and Biology, 2009, 11, 6-14.	2.6	20
116	Imaging Bradykinin B1 Receptor with ⁶⁸ Ga-Labeled [des-Arg ¹⁰]Kallidin Derivatives: Effect of the Linker on Biodistribution and Tumor Uptake. Molecular Pharmaceutics, 2015, 12, 2879-2888.	4.6	20
117	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. Blood, 2015, 126, 579-579.	1.4	20
118	Solid targets for 99mTc production on medical cyclotrons. Journal of Radioanalytical and Nuclear Chemistry, 2014, 299, 1007-1011.	1.5	19
119	N-(n-benzylpiperidin-4-yl)-2-[18f]fluorobenzamide: a potential ligand for pet imaging of breast cancer. Nuclear Medicine and Biology, 2000, 27, 763-767.	0.6	18
120	Assessment of the Novel Estrogen Receptor PET Tracer 4-Fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4FMFES) by PET Imaging in a Breast Cancer Murine Model. Molecular Imaging and Biology, 2013, 15, 625-632.	2.6	18
121	Cross-Linked Polyethylene Clycol Beads to Separate ^{99m} Tc-Pertechnetate from Low-Specific-Activity Molybdenum. Journal of Nuclear Medicine, 2014, 55, 1910-1914.	5.0	18
122	One-step synthesis of 4-[¹⁸ F]fluorobenzyltriphenylphosphonium cation for imaging with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 467-471.	1.0	18
123	Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics. Molecules, 2020, 25, 3854.	3.8	18
124	(18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 57-70.	1.0	18
125	Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets-expectation maximization (OS-EM) reconstruction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 659-61.	2.1	18
126	Cardiac PET imaging of blood flow, metabolism, and function in normal and infarcted rats. IEEE Transactions on Nuclear Science, 2004, 51, 696-704.	2.0	17

#	Article	IF	CITATIONS
127	[18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice. Nuclear Medicine and Biology, 2012, 39, 57-64.	0.6	17
128	Does FDG PET-Assisted Management of Patients With Left Ventricular Dysfunction Improve Quality of Life? A Substudy of the PARR-2 Trial. Canadian Journal of Cardiology, 2012, 28, 54-61.	1.7	17
129	Comparative Studies of Three ⁶⁸ Ga-Labeled [Des-Arg ¹⁰]Kallidin Derivatives for Imaging Bradykinin B1 Receptor Expression with PET. Journal of Nuclear Medicine, 2015, 56, 622-627.	5.0	17
130	PET Metabolic Biomarkers for Cancer. Biomarkers in Cancer, 2016, 8s2, BIC.S27483.	3.6	17
131	Fluorescent Isoindole Crosslink (FIICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction. Angewandte Chemie, 2019, 131, 14258-14262.	2.0	17
132	One-Step ¹⁸ F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging. Journal of Nuclear Medicine, 2019, 60, 1160-1166.	5.0	17
133	The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy Journal of Clinical Oncology, 2011, 29, 8034-8034.	1.6	17
134	Synthesis of 16α-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. Journal of the Chemical Society, Perkin Transactions 1, 2002, , 2275-2281.	1.3	16
135	Automated synthesis of 11β-methoxy-4,16α-[16α-18F]difluoroestradiol (4F-M[18F]FES) for estrogen receptor imaging by positron emission tomography. Nuclear Medicine and Biology, 2007, 34, 459-464.	0.6	16
136	Copper-64 labeled sulfophthalocyanines for positron emission tomography (PET) imaging in tumor-bearing rats. Journal of Porphyrins and Phthalocyanines, 2008, 12, 49-53.	0.8	16
137	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. Haematologica, 2018, 103, e590-e593.	3.5	16
138	Toward ¹⁸ F‣abeled Theranostics: A Single Agent that Can Be Labeled with ¹⁸ F, ⁶⁴ Cu, or ¹⁷⁷ Lu. ChemBioChem, 2020, 21, 943-947.	2.6	16
139	High-Contrast CXCR4-Targeted ¹⁸ F-PET Imaging Using a Potent and Selective Antagonist. Molecular Pharmaceutics, 2021, 18, 187-197.	4.6	16
140	Targeting the Neuropeptide Y1 Receptor for Cancer Imaging by Positron Emission Tomography Using Novel Truncated Peptides. Molecular Pharmaceutics, 2016, 13, 3657-3664.	4.6	15
141	Molybdenum target specifications for cyclotron production of ^{99m} Tc based on patient dose estimates. Physics in Medicine and Biology, 2016, 61, 542-553.	3.0	15
142	[⁶⁸ Ga]Ga/[¹⁷⁷ Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4. Molecular Pharmaceutics, 2019, 16, 4688-4695.	4.6	15
143	2-Fluoropyridine prosthetic compounds for the 18F labeling of bombesin analogues. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3920-3926.	2.2	14
144	Radiolabeled B9958 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography: Effect of the Radiolabel–Chelator Complex on Biodistribution and Tumor Uptake. Molecular Pharmaceutics, 2016, 13, 2823-2832.	4.6	14

#	Article	IF	CITATIONS
145	Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor. Molecular Imaging, 2017, 16, 153601211773791.	1.4	14
146	Flare on Serial Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 213-216.	1.3	14
147	Synthesis and evaluation of 18 F-labeled CJ-042794 for imaging prostanoid EP4 receptor expression in cancer with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2094-2098.	2.2	13
148	Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89 Zr for imaging with positron emission tomography. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 899-905.	2.2	13
149	Segmentation-free direct tumor volume and metabolic activity estimation from PET scans. Computerized Medical Imaging and Graphics, 2018, 63, 52-66.	5.8	13
150	Evaluation of the Tetrakis(3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium(IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of Macromolecular 89Zr-THPN-Conjugates. Inorganic Chemistry, 2019, 58, 14667-14681.	4.0	13
151	Machine Learning in Nuclear Medicine: Part 2—Neural Networks and Clinical Aspects. Journal of Nuclear Medicine, 2021, 62, 22-29.	5.0	13
152	Synthesis and evaluation of 18F-trifluoroborate derivatives of triphenylphosphonium for myocardial perfusion imaging. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1675-1679.	2.2	12
153	An analytical approach of thermodynamic behavior in a gas target system on a medical cyclotron. Applied Radiation and Isotopes, 2016, 107, 252-258.	1.5	12
154	18F-Labeled Cyclized α-Melanocyte-Stimulating Hormone Derivatives for Imaging Human Melanoma Xenograft with Positron Emission Tomography. Scientific Reports, 2019, 9, 13575.	3.3	12
155	¹⁸ F-Branched-Chain Amino Acids: Structure–Activity Relationships and PET Imaging Potential. Journal of Nuclear Medicine, 2019, 60, 1003-1009.	5.0	12
156	Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. Cancer Letters, 2020, 493, 31-40.	7.2	12
157	Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer. Canadian Urological Association Journal, 2020, 15, 162-172.	0.6	12
158	A Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor–Positive Prostate Cancer. Journal of Nuclear Medicine, 2022, 63, 424-430.	5.0	12
159	Preliminary evaluation of 18F-labeled LLP2A-trifluoroborate conjugates as VLA-4 (α4β1 integrin) specific radiotracers for PET imaging of melanoma. Nuclear Medicine and Biology, 2018, 61, 11-20.	0.6	11
160	Thyroid Cancer Presenting as a PET Incidentaloma in a Patient With Concomitant Breast Cancer Metastases to the Thyroid. Clinical Nuclear Medicine, 2006, 31, 382-385.	1.3	10
161	Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES. Nuclear Medicine and Biology, 2007, 34, 325-329.	0.6	10
162	Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 3.	3.9	10

#	Article	IF	CITATIONS
163	Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [18F]AmBF3-TATE. EJNMMI Research, 2020, 10, 25.	2.5	10
164	Steroid Receptor Imaging in Breast Cancer. PET Clinics, 2006, 1, 51-70.	3.0	9
165	Imaging study of using radiopharmaceuticals labeled with cyclotron-produced99mTc. Physics in Medicine and Biology, 2016, 61, 8199-8213.	3.0	9
166	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. Blood, 2010, 116, 854-854.	1.4	9
167	Release of Markers of Myocardial Damage Evaluated in the Coronary Sinus During Cardiac Surgery. Journal of Investigative Medicine, 2007, 55, 195-201.	1.6	8
168	Quantitative hormone therapy follow-up in an ER+/ERαKD mouse tumor model using FDG and [11C]-methionine PET imaging. EJNMMI Research, 2012, 2, 61.	2.5	8
169	89 Zr for antibody labeling and in vivo studies – A comparison between liquid and solid target production. Nuclear Medicine and Biology, 2018, 58, 1-7.	0.6	8
170	Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89. Organic and Biomolecular Chemistry, 2018, 16, 5102-5106.	2.8	8
171	Synthesis and evaluation of an 18F-labeled boramino acid analog of aminosuberic acid for PET imaging of the antiporter system xCâ°'. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3579-3584.	2.2	8
172	Selective Cyclized α-Melanocyte-Stimulating Hormone Derivative with Multiple <i>N</i> -Methylations for Melanoma Imaging with Positron Emission Tomography. ACS Omega, 2020, 5, 10767-10773.	3.5	8
173	Development and biological evaluation of[18F]FMN3PA & [18F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) inÂvivo PET imaging. European Journal of Medicinal Chemistry, 2021, 211, 113005.	5.5	8
174	Automated synthesis of ¹¹ Câ€î²â€hydroxybutyrate by enzymatic conversion of ¹¹ Câ€acetoacetate using βâ€hydroxybutyrate dehydrogenase. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 242-245.	1.0	7
175	A fast and simple dose-calibrator-based quality control test for the radionuclidic purity of cyclotron-produced ^{99m} Tc. Physics in Medicine and Biology, 2015, 60, 8229-8247.	3.0	7
176	Radiolabeled R954 Derivatives for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography. Molecular Pharmaceutics, 2017, 14, 821-829.	4.6	7
177	Improving the stability of 11C–labeled L-methionine with ascorbate. EJNMMI Radiopharmacy and Chemistry, 2017, 2, 13.	3.9	7
178	18F-DCFPyL PET/CT in Oncocytoma. Clinical Nuclear Medicine, 2018, 43, 921-924.	1.3	7
179	Comparison of biological properties of [¹⁷⁷ Lu]Luâ€ProBOMB1 and [¹⁷⁷ Lu]Luâ€NeoBOMB1 for GRPR targeting. Journal of Labelled Compounds and Radiopharmaceuticals, 2020, 63, 56-64.	1.0	7
180	Impact of image reconstruction method on dose distributions derived from ⁹⁰ Y PET images: phantom and liver radioembolization patient studies. Physics in Medicine and Biology, 2020, 65, 215022.	3.0	7

4

#	Article	IF	CITATIONS
181	Detection of Unsuspected Recurrent Lymphoma With Fluorodeoxyglucose-Positron Emission Tomographic Imaging After Induction Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 126-128.	1.3	7
182	Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells. RSC Chemical Biology, 2022, 3, 69-78.	4.1	7
183	Fluorine-18–Labeled Deoxyglucose Positron Emission Tomography in the Diagnosis and Management of Aortitis With Pulmonary Artery Involvement. Circulation, 2005, 111, e375-6.	1.6	6
184	Design, synthesis and evaluation of 18F-labeled bradykinin B1 receptor-targeting small molecules for PET imaging. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4095-4100.	2.2	6
185	Addressing Chirality in the Structure and Synthesis of [¹⁸ F]5â€Fluoroaminosuberic Acid ([¹⁸ F]FASu). Chemistry - A European Journal, 2017, 23, 11100-11107.	3.3	6
186	Synthesis and evaluation of an ¹⁸ Fâ€labeled trifluoroborate derivative of 2â€nitroimidazole for imaging tumor hypoxia with positron emission tomography. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 370-379.	1.0	6
187	^t Bu ₄ octapa-alkyl-NHS for metalloradiopeptide preparation. Dalton Transactions, 2020, 49, 7605-7619.	3.3	6
188	Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. Clinical Cancer Research, 2022, 28, 1628-1639.	7.0	6
189	False-positive 201thallium study in Wolff-Parkinson-White syndrome. Canadian Journal of Cardiology, 1996, 12, 499-502.	1.7	6
190	68Ca-Labeled [Leu13ï^Thz14]Bombesin(7–14) Derivatives: Promising GRPR-Targeting PET Tracers with Low Pancreas Uptake. Molecules, 2022, 27, 3777.	3.8	6
191	The Effect of Chirality on the Application of 5-[18F]Fluoro-Aminosuberic Acid ([18F]FASu) for Oxidative Stress Imaging. Molecular Imaging and Biology, 2020, 22, 873-882.	2.6	5
192	Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Correlated With Computed Tomographic Scan and Magnetic Resonance Imaging in a Case of Hematometrocolpos. Clinical Nuclear Medicine, 2000, 25, 486-487.	1.3	5
193	Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer. PET Clinics, 2022, 17, 77-84.	3.0	5
194	Isolation and characterization of monoclonal antibodies against human carbonic anhydrase-IX. MAbs, 2021, 13, 1999194.	5.2	5
195	Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen–Positron Emission Tomography and Computed Tomography Imaging. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1126-1134.	0.8	5
196	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer, 2022, 22, 251.	2.6	5
197	PHTHALOCYANINE AND NAPHTHALOCYANINE PHOTOSENSITIZED OXIDATION OF 2'-DEOXYGUANOSINE: DISTINCT TYPE I AND TYPE II PRODUCTS. Photochemistry and Photobiology, 1984, 39, 809-814.	2.5	4

A comparison of segmentation and emission subtraction for singles transmission in PET. , 0, , .

#	Article	IF	CITATIONS
199	Impact of F-18 Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography on Oncologic Patient Management: First 2 Years' Experience at a Single Canadian Cancer Center. Canadian Association of Radiologists Journal, 2010, 61, 13-18.	2.0	4
200	Producing radiometals in liquid targets: Proof of feasibility with [sup 94m]Tc. , 2012, , .		4
201	Graphical user interface for yield and dose estimations for cyclotron-produced technetium. Physics in Medicine and Biology, 2014, 59, 3337-3352.	3.0	4
202	Quantitative analysis of relationships between irradiation parameters and the reproducibility of cyclotron-produced99mTc yields. Physics in Medicine and Biology, 2015, 60, 3883-3903.	3.0	4
203	Non-invasive Use of Positron Emission Tomography to Monitor Diethyl maleate and Radiation-Induced Changes in System xCâ^' Activity in Breast Cancer. Molecular Imaging and Biology, 2019, 21, 1107-1116.	2.6	4
204	Synthesis and 18F-radiolabeling of thymidine AMBF3 conjugates. RSC Medicinal Chemistry, 2020, 11, 569-576.	3.9	4
205	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Advances, 2021, 5, 3647-3655.	5.2	4
206	Synthesis of 2, 16α―and 4, 16αâ€{16αâ€ ¹⁸ F]difluoroestradiols and their 11βâ€methoxy derivat estrogen receptor imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S348.	ives for 1.0	3
207	16α-[18F]-fluoro-17ß-oestradiol ([18F]FES): A biomarker for imaging oestrogen receptor expression with positron emission tomography (PET). Medecine Nucleaire, 2015, 39, 64-70.	0.2	3
208	Synthesis and evaluation of 18 F-labeled 4-nitrobenzyl derivatives for imaging tumor hypoxia with positron emission tomography: Comparison of 2-[18 F]fluoroethyl carbonate and 2-[18 F]fluoroethyl carbamate. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 584-588.	2.2	3
209	2-18F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion. Journal of Nuclear Medicine, 2017, 58, 815-820.	5.0	3
210	Modeling the pressure rise of a liquid target on a medical cyclotron: Steady-state analysis. Applied Radiation and Isotopes, 2017, 120, 22-29.	1.5	3
211	Synthesis and evaluation of a 68Ga-labeled bradykinin B1 receptor agonist for imaging with positron emission tomography. Bioorganic and Medicinal Chemistry, 2017, 25, 690-696.	3.0	3
212	[²¹³ Bi]Bi ³⁺ /[¹¹¹ In]In ³⁺ -neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma─Structural, Radiochemical, and Biological Evaluation. Bioconjugate Chemistry, 2022, 33, 505-522.	3.6	3
213	Trastuzumab-conjugated oxine-based ligand for [89Zr]Zr4+ immunoPET. Journal of Inorganic Biochemistry, 2022, , 111936.	3.5	3
214	Determination of scatter characteristics generated from out of FOV source in FDG-PET studies. , 0, , .		2
215	A new transfer system for solid targets. , 2012, , .		2
216	A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the xCâ ⁻²	2.2	2

A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the xCá transporter. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5512-5515. 216

#	Article	IF	CITATIONS
217	Tumor Lesion Segmentation from 3D PET Using a Machine Learning Driven Active Surface. Lecture Notes in Computer Science, 2016, , 271-278.	1.3	2
218	Patterns of Prostate Cancer Recurrence after Brachytherapy Imaged with PSMA-Targeting 18F-Dcfpyl PET/CT. International Journal of Radiation Oncology Biology Physics, 2019, 105, E304-E305.	0.8	2
219	Analysis of radioactive waste generated during the cyclotron production of 99mTc. Physics in Medicine and Biology, 2019, 64, 055008.	3.0	2
220	Evaluation of ¹⁸ F-EF5 for detection of hypoxia in localized adenocarcinoma of the prostate. Acta Oncológica, 2021, 60, 1489-1498.	1.8	2
221	Extensive F-18 FDG Uptake in Metastatic Spindle Cell Carcinoma of the Lung. Clinical Nuclear Medicine, 2001, 26, 79-80.	1.3	2
222	Quantitative evaluation of PSMA PET imaging using a realistic anthropomorphic phantom and shell-less radioactive epoxy lesions. EJNMMI Physics, 2022, 9, 2.	2.7	2
223	Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging. EJNMMI Radiopharmacy and Chemistry, 2022, 7, .	3.9	2
224	Receptor Imaging in Patients with Breast Cancer. PET Clinics, 2009, 4, 329-341.	3.0	1
225	Liquid Xenon Detectors for Positron Emission Tomography. Journal of Physics: Conference Series, 2011, 312, 062006.	0.4	1
226	LONG TERM FOLLOW UP OF OUTCOMES WITH F-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IMAGING- ASSISTED MANAGEMENT OF PATIENTS WITH SEVERE LEFT VENTRICULAR DYSFUNCTION SECONDARY TO CORONARY DISEASE: 5-YEAR FOLLOW-UP OF THE PARR-2 RANDOMIZED CONTROLLED TRIAL. Canadian Journal of Cardiology, 2014, 30, S266.	1.7	1
227	Primary myxoid sarcoma of the pleura. Canadian Journal of Surgery, 2009, 52, E93-E94.	1.2	1
228	Tl-201 Chloride Bone Marrow Uptake in a Patient With Minor Thalassemia. Clinical Nuclear Medicine, 1994, 19, 822-823.	1.3	0
229	Singles transmission scans performed post-injection for quantitative whole body FDG-PET. , 0, , .		Ο
230	The Clinical Impact of FDG-PET Imaging on the Management of Lung Cancer Patients in a New Canadian PET Center. Molecular Imaging and Biology, 1999, 2, 349.	0.3	0
231	Coupling of /sup 11/C-acetate and /sup 13/N-ammonia for measurement of myocardial blood flow in normal rats using the Sherbrooke PET scanner. , 0, , .		0
232	Cardiac PET imaging of blood flow, metabolism and function in normal and infarcted rats. , 0, , .		0
233	577 The role of fluorodeoxyglucose positron emission tomography guided management in improving quality of life amongst patients with ischemic left ventricular dysfunction. Canadian Journal of Cardiology, 2011, 27, S269-S270.	1.7	0
234	Comparison of High-grade Clioma Relapses With Radiation Therapy Target Volumes Obtained From MRI and 18 F-FDOPA PET. International Journal of Radiation Oncology Biology Physics, 2012, 84, S270-S271.	0.8	0

#	Article	IF	CITATIONS
235	Graphical user interface for yield and doses estimations for cyclotron technetium production. , 2013, , ,		0
236	Radionuclidic purity measurements for cyclotron-produced 99mTc via 100Mo(p,2n) at 18â€MeV. AIP Conference Proceedings, 2017, , .	0.4	0
237	FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter. Clinical Cancer Research, 2017, 23, 3474-3474.	7.0	0
238	Cyclotron-based production of Tc-99m and other metals. Nuclear Medicine and Biology, 2019, 72-73, S6-S7.	0.6	0
239	Innenrücktitelbild: Fluorescent Isoindole Crosslink (FIICk) Chemistry: A Rapid, Userâ€friendly Stapling Reaction (Angew. Chem. 40/2019). Angewandte Chemie, 2019, 131, 14527-14527.	2.0	0
240	Organoboronates. , 2019, , 519-549.		0
241	MO-F-110-08: Yields and Dosimetry Estimates for Radioisotopes Produced in Proton-Induced Reactions on Enriched Molybdenum Targets. Medical Physics, 2011, 38, 3729-3729.	3.0	0
242	WE-G-214-08: Interobserver Volume Variations in the Target Delineation of High-Grade Gliomas Using Magnetic Resonance Imaging and 18F-FDOPA Positron Emission Tomography. Medical Physics, 2011, 38, 3832-3832.	3.0	0
243	La mesure de l'APS demeure essentielle. Canadian Urological Association Journal, 2011, 5, 378-378.	0.6	0
244	TH-C-141-06: Estimating Cell Density Using Fractional Anisotropy From Postoperative Diffusion Tensor Imaging of High-Grade Gliomas. Medical Physics, 2013, 40, 540-540.	3.0	0
245	FDG-PET IMAGING: AN AID TO THE CLINICIAN IN THE MANAGEMENT OF PAINFUL HIP PROSTHESES Clinical Nuclear Medicine, 1998, 23, 791.	1.3	0
246	Radiolabeled Antibodies for Cancer Radioimmunotherapy. , 2022, , 297-345.		0
247	The challenges of improving breast cancer outcome with diagnostic imaging techniques. Oncology, 2009, 23, 264, 266.	0.5	0